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Parkinson's diseaseThe pathological interaction of intrinsically disordered proteins, such asα-synuclein (SYN) and Tubulin Polymer-
ization Promoting Protein (TPPP/p25), is often associatedwith neurodegenerative disorders. These hallmark pro-
teins are co-enriched and co-localized in brain inclusions of Parkinson's disease and other synucleinopathies; yet,
their successful targeting does not provide adequate effect due to theirmultiple functions. Herewe characterized
the interactions of the human recombinant wild type SYN, its truncated forms (SYN1–120, SYN95–140), a
synthetized peptide (SYN126–140) and a proteolytic fragment (SYN103–140) with TPPP/p25 to identify the SYN seg-
ment involved in the interaction. The binding of SYN103–140 to TPPP/p25 detected by ELISA suggested the involve-
ment of a segment within the C-terminal of SYN. The studies performed with ELISA, Microscale Thermophoresis
and afﬁnity chromatography proved that SYN95–140 and SYN126–140 – in contrast to SYN1–120 – displayed signiﬁ-
cant binding to TPPP/p25. Fluorescence assay with ANS, a molten globule indicator, showed that SYN, but not
SYN1–120 abolished the zinc-induced local folding of both the full length as well as the N- and C-terminal-free
(core) TPPP/p25; SYN95–140 and SYN126–140 were effective as well. The aggregation-prone properties of the SYN
species with full length or core TPPP/p25 visualized by immunoﬂuorescent microscopy demonstrated that
SYN95–140 and SYN126–140, but not SYN1–120, induced co-enrichment and massive intracellular aggregation after
their premixing and uptake from the medium. These data with their innovative impact could contribute to the
development of anti-Parkinson drugs with unique speciﬁcity by targeting the interface of the pathological
TPPP/p25-SYN complex.
© 2015 Published by Elsevier B.V.1. Introduction
The intrinsically disorderedα-synuclein (SYN) and Tubulin Polymer-
ization Promoting Protein/p25 (TPPP/p25) are extensively involved in
the etiology of Parkinson's disease and other synucleinopathies [1–3].
Therapeutic targeting of these proteins by smallmolecules is a huge chal-
lenge because of their ﬂexibility resulting in heterogeneous conforma-
tional states. In addition, these and many other disordered proteins
display multiple, independent functions [1,4–6]. The various functions
of these moonlighting proteins are not coded at gene level, do not stem
from genetic alterations, their functions are manifested themselves at
protein level due to changes in cellular localization, cell type, their oligo-
meric state, and concentrations of substrates, cofactors or products [7]. A
subclass of themoonlighting proteins are the Neomorphic Moonlighting, Research Centre for Natural
yar tudósok körútja 2., H-1117,
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@ttk.mta.hu (A. Szabó),Proteins (NMPs), the physiological function of which can be converted
into a pathological one mostly due to their hetero-associations with
“pathological” partners distinct from the physiological ones [8,9]. Thus,
disordered proteins hallmarking conformational diseases are often be-
long to NMPs; the prototype of these proteins is the TPPP/p25. This ﬁnd-
ing leads us to the recognition that targeting the individual disordered
proteins themselves does not seem to be a promising approach to the de-
velopment of therapeutic treatments of Parkinson's disease.
TPPP/p25 is a brain-speciﬁc protein discovered in our laboratory as a
tubulin binding protein, which modulates the dynamics and stability of
the microtubule system by its bundling and acetylation-enhancing ac-
tivities [10–12]. In normal brain, it plays a crucial role in the differenti-
ation of the oligodendrocytes thus likely in the ensheathment of axons
as well [13,14]. In addition, TPPP/p25 is involved in the aggresome for-
mation at the centrosome region, which functions as a cytoprotective
mechanism by collecting the small toxic protein aggregates [11,15].
The optimal intracellular expression of TPPP/p25 is a key factor in the
physiology of the brain functions; either its lack or enrichment in oligo-
dendrocytes leads to distinct CNS diseases: glioma andmultiple system
atrophy (MSA), respectively [2,16]. The pathomechanism of these neu-
rological disorders hallmarked by SYN and TPPP/p25 has not been clar-
iﬁed in details.
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the binding of SYN forming the pathological complex, but not for the
binding with tubulin/microtubules forming the physiological one [17–
19]. The structure of the disordered SYN has been characterized as
well; it is constituted of 3 well-deﬁned regions [20]. Two separate,
non-interacting zinc binding sites have been identiﬁed within the SYN
sequence, 50H and 121DNE123 at the N- and C-terminals, respectively
[21]. Functionally, SYN stimulates the phosphorylation of tau, which
could indirectly affect the stability of axonal microtubules. The involve-
ment of the C-terminal 45 residues of SYN in its aggregation at extreme
in vitro conditions was suggested; however, a 30-residue peptide was
found to be ineffective as a competitor [22]. At physiological conditions,
TPPP/p25 occurs in oligodendrocytes [13], while SYN is expressed in
neurons [23,24]; however, at pathological conditions these twoproteins
are enriched and co-localized in both cell types [2]. The mechanism of
these processes is unknown; however, there are data that SYN could
be taken up by cells from the medium, in addition, it could be
transported via exosomal cell-to-cell transmission [24–27]. Our recent
data have shown that TPPP/p25 could also be taken up similarly to
SYN [9]; moreover, it could be detected in the cerebrospinal ﬂuid [28].
Recentlywe have characterized the interactions of TPPP/p25with its
physiological partners as well as with proteins hallmarking Parkinson's
disease [9,29]. The tight interaction of TPPP/p25 with SYN in vitro as
well as itsmodest aggregation-promoting activitywas also demonstrat-
ed inHeLa andCHO cells expressing TPPP/p25 ectopically [9]. In a recent
paper, we have identiﬁed the TPPP/p25 segment involved in the contact
surface at different organization levels using human recombinant wild
type and mutant proteins and their fragments [9]. Here we identiﬁed
a segment of the SYN involved in the formation of the pathological
SYN-TPPP/p25 complex and characterized the functional consequences
atmolecular and cellular levels using human recombinantwild type and
truncated proteins, proteolytic fragments and synthetized peptide as
well as CHO10 cell culture.
2. Materials and methods
2.1. Antibodies, peptides
The following antibodies were used: mouse monoclonal SYN anti-
body against the epitope of 121–125 aa (Sigma, S5566, clone Syn211),
rabbit polyclonal SYN antibody developed against the 111–132 peptide
sequence in the C-terminal of the protein (Sigma, S3062) or rabbit
monoclonal SYN antibody developed against the N-terminal of SYN
(Merck, 04–1053, clone EP1646Y); rat polyclonal TPPP/p25 antibody
[2]. SYN126–140 peptide (EMPSEEGYQDYEPEA) and FITC-labeled peptide
(FITC-EMPSEEGYQDYEPEA) were purchased from ChinaPeptides
(Shanghai, China).
2.2. DNA manipulations
Prokaryotic expression vector containing the insert for human full
length TPPP/p25 was prepared and puriﬁed as described previously
[12]. The double truncated TPPP/p25 corresponding to amino acid resi-
dues 44–174 (TPPP/p25 Δ3–43/Δ175–219) was prepared and puriﬁed
as described previously [9].
The truncated human SYN corresponding to amino acid residues 1–
120 (SYN1–120)was ampliﬁed by polymerase chain reaction (PCR) using
forward primer 5′-GAAGGAGATATACATATGGATGTATTCATGAAAG
GAC-3′ and reverse primer 5′-TTCATAAGCAAGCTTTTAAGGATCCACA
GGCATATCTTCC-3′ and pT7-7 SYN wt [30] as a template. The truncated
form was made by replacing the wild type SYN cDNA. After digestion
with NdeI and HindIII restriction enzymes, the insert was ligated into
pT7-7 vector [31]. The C-terminal human SYN peptide corresponding
to amino acid residues 95–140with aHis-tag (SYN95–140)was ampliﬁed
by PCR using forward primer 5′-CAGCCACTCATATGGTCAAAAAGGACCA
GTTGGGC-3′ and reverse primer 5′-AGATATCTCGAGGGCTTCAGGTTCGTAGTCTTGATACC-3′ and pT7-7 SYN wt as a template. After digestion
with NdeI and XhoI restriction enzymes, inserts were ligated into
pET21c vector (Novagen).
Structures and sequences of all constructs were veriﬁed by restric-
tion mapping and DNA sequencing.
2.3. Expression and puriﬁcation of the human wild type and truncated
TPPP/p25
Human recombinant full length and double truncated TPPP/p25
forms possessing a His-tag were expressed in Escherichia coli BL21
(DE3) cells and isolated on HIS-Select™ Cartridge (Sigma-Aldrich) as
described previously [2,32]. Protein concentrations were determined
from the absorbance at 280 nm using an extinction coefﬁcient of
10,095 M−1 *cm−1 and 5625 M−1 *cm−1 for TPPP/p25 and double
truncated TPPP/p25, respectively.
2.4. Expression and puriﬁcation of the human wild type and truncated SYN
Human recombinant full length and truncated SYN forms were
expressed in ampicillin-resistant E. coli BL21 DE3 cells. Following trans-
formation, BL21-competent cells were grown in LB in the presence of
ampicillin (100 μg/ml). Cells were induced with 1 mM isopropyl β-D-
1-thiogalactopyranoside, cultured at 37 °C for 2.5 h and harvested by
centrifugation (20 min, 4 °C, 2000 g).
Human recombinant SYN was isolated as described previously [33].
Brieﬂy, the cell pellet was resuspended in buffer A (20 mM Tris–HCl
buffer pH 7.5 containing 1 mM ethylenediaminetetraacetic acid and
50 mM NaCl) with 5 mM 2-mercaptoethanol, 10 μM 4-(2-aminoethyl)
benzenesulfonyl ﬂuoride hydrochloride, 1 mM benzamidine, 1 μg/ml
pepstatin and 1 μg/ml leupeptin; and lysed by sonication. After centrifu-
gation (25min, 4 °C, 39,000 g), the cell suspension was kept at 90 °C for
10 min, and centrifuged again (25 min, 4 °C, 39,000 g). The supernatant
was loaded to a DE52 column equilibratedwith buffer A. After extensive
washing, SYNwas elutedwith 20mMTris–HCl buffer pH 7.5 containing
1 mM ethylenediaminetetraacetic acid and 150 mM NaCl.
SYN1–120was prepared as the full length SYN except that the cell pel-
let was resuspended in buffer B (20mMTris–HCl buffer pH 8.0 contain-
ing 1 mM ethylenediaminetetraacetic acid and 10 mM NaCl) and the
ﬂow-through fraction was collected during chromatography.
The C-terminal SYN fragment possessing a His-tag (SYN95–140) was
isolated on HIS-Select™ Cartridge (Sigma-Aldrich) similarly as de-
scribed for TPPP/p25 [2,32].
The proteins were concentrated with a YM 3 Diaﬂo membrane
(Amicon, Danvers, MA), dialyzed overnight in 50 mM NH4-acetate, ly-
ophilized and stored at −80 °C. The purity of proteins was analyzed
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Protein concentration was calculated from the absorbance at
280 nm using an extinction coefﬁcient of 5960 M−1 *cm−1, 2980 M−1
*cm−1 and 4470 M−1 *cm−1 for SYN, SYN1–120 and the C-terminal
SYN95–140, respectively. Extinction coefﬁcients were calculated using
ProtParam (http://web.expasy.org/cgi-bin/protparam/protparam).
2.5. Limited proteolysis
SYN at 2 mg/ml was digested with 5 μg/ml trypsin (Sigma-Aldrich)
in 40 mM phosphate buffer pH 7.4 at room temperature. The digestion
was terminated by 15 μg/ml soybean trypsin inhibitor (Sigma-Aldrich).
The samples were analyzed by SDS-PAGE, separated on a Tricine-
containing two-layer-gel [34] and stained with Coomassie Brilliant
Blue R-250 containing 2-mercaptoethanol.
2.6. Enzyme-linked immunosorbent assay (ELISA)
The plate was coated with 5 μg/ml (50 μl/well) TPPP/p25 or SYN
forms in phosphate buffered saline (PBS) as described previously [9,
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the immobilized proteins were incubated with serial dilutions of SYN/
digested SYN/truncated SYN forms or TPPP/p25 followed by the addi-
tion of either SYN or TPPP/p25 antibody and the corresponding peroxi-
dase conjugated secondary IgG. The bound antibodies were detected
using o-phenylenediamine as substrate. The reaction was stopped
after 10 min with 1 M H2SO4, and the absorbance was read at 490 nm
with an EnSpire Multimode Reader (Perkin Elmer). The binding con-
stants (Kd) were evaluated from the saturation curves by non-linear
curveﬁtting assuming single binding site hyperbolamodel using theOr-
igin 8.0 software.
In the case of the competitive ELISA, the TPPP/p25 preincubated for
30 min without or with 1 μM SYN/digested SYN/truncated SYN forms
or 50 μM SYN126–140 peptide at constant concentration was added to
the immobilized SYN. The bound TPPP/p25 was quantiﬁed by anti-
TPPP/p25 antibody as described above. SYN was digested with trypsin
for 60 min.
2.7. 8-Anilinonaphthalene-1-sulfonic acid (ANS) ﬂuorescence
The ﬂuorescence measurements were performed in 50 mM Tris buff-
er, pH 7.5 using a Jobin Yvon Fluoromax-3 spectroﬂuorometer (Jobin
Yvon Horiba, Longiumeau, France) at 25 °C. The ﬂuorophore was excited
at 380 nm, emission was monitored from 400 to 600 nm as described in
[18]. All measurements were done in triplicate. Data were processed
using DataMax software. A blank spectrumwithout proteinwas recorded
before addition of the wild type and double truncated TPPP/p25 forms.
The concentration of ANS, TPPP/p25/double truncated TPPP/p25 and
ZnCl2 was 50 μM, 2.5 μM and 20 μM, respectively. The concentrations of
distinct SYN forms were varied as indicated in the ﬁgure legends.
2.8. Afﬁnity chromatography
SYN was immobilized to CNBr-activated Sepharose 4B (Amersham)
according to the manufacturer's instructions. The SYN bound to Sepha-
rose was packed into columns. The binding capacity of a column was
~1.5 mg SYN per 1 ml Sepharose (column volume ~2 ml). The afﬁnity
column was equilibrated with phosphate buffer (10 mM phosphate
buffer pH 7.4 containing 10 mM NaCl). 0.5 mg TPPP/p25 without or
with 0.5 mg SYN or SYN1–120 in 500 μl was loaded to the column, and
the column was washed with phosphate buffer (10 ml, 1 ml fractions).
The bound proteins were eluted with phosphate buffer containing
100 mMNaCl (5 ml, 1 ml fractions). After each experiment the column
was regenerated using 3 cycles of 0.1 M Na-acetate pH 4.0 buffer con-
taining 0.5 M NaCl and 0.1 M Tris pH 8.0 buffer containing 0.5 M NaCl.
Theﬂow-through (unbound) and the eluted (bound) fractionswere an-
alyzed by SDS-PAGE.
2.9. Microscale thermophoresis (MST)
Human recombinant TPPP/p25 was labeled with the Monolith
NT.115 protein labeling kit (NanoTemper Technologies, Germany)
using the amine reactive, red ﬂuorescent dye NT-647 NHS according
to the manufacturer's instructions. Labeled protein was separated
from the unreacted, free dye by buffer-exchange column chromatogra-
phy. The labeled TPPP/p25 and the various SYN stock solutions were
centrifuged at 17,000 g for 5 min at room temperature prior to the as-
says. Experiments were carried out in 10 mM phosphate buffer pH 7.4
containing 10 mM NaCl, 0.5 mg/ml BSA and 0.1% Tween-20 with a
Monolith NT.115 Microscale Thermophoresis Red/Blue instrument
using hydrophobic capillaries (NanoTemper Technologies, Germany).
The ﬂuorescence signal was kept above 200 units by modifying the
LED power between 20 and 50%.
The dilution series of the SYN, SYN95–140 or SYN120–140 yielded 16
different protein concentrations starting from 5 to 20 μM; the concen-
tration of the labeled TPPP/p25 was kept constant (15 nM). After5 min incubation at room temperature, the samples were loaded into
capillaries. Thermophoresis and temperature-jump was measured at
25 °C for 30 s with 20–50% LED power and 40% MST power, LED color
was set to red. Fluorescence emission was recorded for 5 s before and
after the laser was switched on with data collection throughout; while
the delay was set to 25 s. Data were normalized to an arbitrary initial
ﬂuorescence value. The MST signal detects the binding based on the
change in the normalized ﬂuorescence [35–37].
2.10. Cell culture and manipulation
CHO10 cells were cultured in DMEM supplemented with 10% fetal
calf serum, 100 units/ml streptomycin and 100 μg/ml penicillin (all re-
agents from Sigma) in a humidiﬁed incubator at 37 °C with 5% CO2 [11,
12]. For microscopic analysis, cells were grown on 12 mm diameter cov-
erslips. The uptake of the human recombinant TPPP/p25 and/or SYN spe-
cies were as follows: 3 μl and 12 μl were premixed from 1 mg/ml stock
solutions of the full length or double truncated forms of TPPP/p25 and
SYN, respectively, then added to 500 μl medium and incubated for 3 h.
The ﬁnal concentration of the full length species of TPPP/p25 and SYN
were 0.24 μM and 1.68 μM, respectively. In the case of FITC labeled pep-
tide, 1 μl of a 10 μg/μl (440 μM) stockwas usedwith the TPPP/p25 forms.
2.11. Immunocytochemistry
After treatment, CHO10 cells were ﬁxed with ice-cold methanol for
10 min, followed by postﬁxation with 4% formaldehyde (Sigma-
252,549) for 10 min. After washes with PBS (3 × 10 min), samples
were blocked for 30 min in PBS with 30 μM digitonin containing 5%
fetal calf serum. Subsequently, the cellswere stainedwithmousemono-
clonal antibody against SYN (epitope of 121–125 aa, Sigma-Aldrich,
clone Syn211) or rabbit monoclonal against the N-terminal of SYN
(Merck, 04–1053) and polyclonal rat sera against human recombinant
TPPP/p25 [2] followed by Alexa 488 conjugated anti-mouse antibody
and Alexa 546 conjugated anti-rat antibody (Invitrogen). The samples
were washed thrice with PBS for 10 min after antibody incubation. To
detect the FITC-labeled peptide, its intrinsic ﬂuorescence was used. Nu-
clei were counterstained with 4,6-diamidino-2-phenylindole. Images of
ﬁxed samples were acquired on a Leica DMLS microscope.
2.12. Statistical analysis
The error bars represent the standard error of themean (SEM). Com-
parisonswere performed using the unpaired Student's t-test and values
were considered to be signiﬁcant if the calculated p valuewas b0.05 (*).
3. Results and discussion
Recently we have reported that SYN binds to the full length and dou-
ble truncated (N- and C-terminal free) TPPP/p25 [9]. While the double
truncated formdisplays very low tubulin binding, tubulin polymerization
promoting and microtubule bundling activities, its SYN binding and ag-
gregation promoting activity is maintained [9]. The 147–156 aa segment
of TPPP/p25 has been suggested to be involved in SYN binding [9].
3.1. Identiﬁcation of the SYN segment involved in TPPP/p25 binding
In order to obtain information on the segment of SYN involved in the
binding of TPPP/p25, trypsin was selected as a protease with its well-
deﬁned cleavage speciﬁcity. The binding of SYN fragments to TPPP/
p25was tested by ELISA using a speciﬁc anti-SYN antibody with an epi-
tope at the C-terminal tail of the protein. A fragment can display
immunopositivity if it contains both the epitope and the TPPP/p25 bind-
ing segment. This segment of SYN103–140 contains the epitopes of both
mono- and polyclonal anti-SYN antibodies as shown in Fig. 1A.
Fig. 1. Binding of tryptic fragments of SYN to TPPP/p25. (A) Tryptic fragment of SYN containing the epitopes of mouse monoclonal (bold) and rabbit polyclonal (underlined) anti-SYN an-
tibodies. (B) Representative SDS-PAGE image of the time-dependent limited proteolysis of SYN. (C) Binding of the SYN (●) and its fragments obtained by digestion for 60min (△) to the
immobilized TPPP/p25 as detected by polyclonal anti-SYN antibody in ELISA experiment. Error bars represent SEM (n=3–6). (D) Inhibitory effect of the SYN fragments on the interaction
of TPPP/p25with SYN. TPPP/p25 at different concentrationswas preincubatedwithout (white column) orwith 1 μMSYN (black column), or its fragments (gray column), and added to the
immobilized SYN. The ELISA data were normalized with respect to TPPP/p25 at 0.125 μMwithout SYN. Error bars represent SEM (n = 3–4).
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(Fig. 1B); the number and intensity of the peptide bands could be de-
tected in the course of digestions. At 60min no intact SYNwas detected,
which could produce false positive result.
Fig. 1C shows the ELISA experiments; in one set of experiments TPPP/
p25was immobilized on theplate, andSYNordigested SYNsampleswere
added in various concentrations; the bound SYN/SYN fragmentswere de-
tected using anti-SYN antibody developed against the 111–132 peptide
sequence in the C-terminus. Themixtures of the SYN fragments obtained
by digestion for 60min displayed immunopositivity, even if it was signif-
icantly lower as compared to that of wild type. This ﬁnding suggests that
there is a tryptic fragment comprising the epitope of the anti-SYN anti-
body and the binding segment of TPPP/p25.
In another set of experiments the inhibitory potency of the trypsin
digested SYN was tested by a competitive ELISA (Fig. 1D). TPPP/p25
premixed without or with SYN/SYN fragments was added to intact SYN
immobilized on theELISAplate; the concentrations of TPPP/p25were var-
ied in thewells but the concentration of the SYN/SYN fragmentswas kept
constant. The association of TPPP/p25 to the immobilized SYN in the pres-
ence of SYN/fragments was detected by an anti-TPPP/p25 antibody. As
shown in Fig. 1D, the trypsin digest contains active fragment(s), which
can partially inhibit the hetero-association of the two full length proteins
in a concentration dependent manner. These data suggest that the bind-
ing motive of SYN involved in the interaction with TPPP/p25 is within
the 103–140 aa segment of the C-terminal (SYN103–140).3.2. Inhibitory effect of the SYN truncation on the binding of TPPP/p25 to
SYN afﬁnity column
Human recombinant SYN mutants as illustrated in Fig. 2 produced
by recombinant techniques as described in the Materials and methodswere used to localize the SYN segment within the SYN103–140 fragment
involved in the binding of TPPP/p25.
In this set of experiments, SYN was immobilized on CNBr-activated
Sepharose 4B column as described in theMaterials andmethods. The af-
ﬁnity column was equilibrated with 10 mM phosphate buffer, pH 7.4,
containing 10 mM NaCl. TPPP/p25 was loaded to the column, which
retained the protein according to its capacity (Fig. 3A). When TPPP/p25
premixed with SYN or SYN1–120 were loaded to the column, the binding
of the TPPP/p25 to the immobilized SYN was highly dependent on the
presence of the C-terminal SYN segment (Fig. 3). As illustrated in Fig. 3,
the presence of SYN signiﬁcantly reduced the TPPP/p25 binding due to
its powerful competitor capacity. While SYN1–120 did not prevent the
binding of TPPP/p25, it was still eluted by 100mMNaCl containing buff-
er, and the afﬁnity column TPPP/p25 binding capacitywas similar to that
as in the absence of the competitor SYN. These data indicate the potential
role of the 121–140 segment of SYN in the formation of the pathological
complex that is stabilized by salt-sensitive electrostatic interactions be-
tween the acidic SYN and the basic TPPP/p25. Previously we reported
that the binding of TPPP/p25 to its physiological partner, tubulin, is also
salt-sensitive; 150 mMNaCl signiﬁcantly reduced the binding of tubulin
to a TPPP/p25 afﬁnity column [38], although their interactions have been
proved both in vitro [10,32] and in different cell lines [9,11,39].
3.3. Binding potency of the C-terminal truncated SYN mutants to TPPP/p25
Fig. 4A shows an ELISA experiment in which the binding potency of
the truncated forms of SYN was established as compared with that of
the full length SYN. SYN species were immobilized on the plate, and
then TPPP/p25 was added at different concentrations. Complex forma-
tion was detected by a speciﬁc polyclonal anti-TPPP/p25 antibody
with multiple epitopes [2]. The titration data show that SYN95–140 has
similar potency as that of SYN to bind to TPPP/p25, while the SYN1–120
Fig. 2. Characterization of the different SYNmutants. (A) Schematic representation of thevarious SYNmutants. (B) A representative SDS-PAGE of the SYNmutants. 2 μg proteinwas loaded to
each lane. MM: molecular weight marker. (C) Immunopositivity of the SYN mutants with antibodies of epitopes in the N-terminal (black column) and C-terminal (121DNEAY125, white
column) as detected by ELISA experiment. The plate was coated with SYN or its mutant forms, and the interaction was detected by SYN antibodies. Error bars represent SEM (n = 3–5).
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121–140 aa segment in the complex formation.
In another set of experiments, the inhibitory potency of the different
truncated SYN forms was analyzed by competitive ELISA (Fig. 4B). TPPP/
p25 premixed without or with SYN species at a constant concentration
was added to intact SYN immobilized on the ELISA plate, and the effects
were detected by an anti-TPPP/p25 antibody similarly as in Fig. 1D. As
shown in Fig. 4B, all SYN species with the exception of SYN1−120 display
signiﬁcant inhibition on the hetero-association of the two full length pro-
tein,which also support that the bindingmotive of SYN involved in the in-
teraction with TPPP/p25 is within the 121–140 aa segment of the C-
terminal.
MST experiments also provided evidence for the role of the unfolded
segment of SYN in the pathological interaction with TPPP/p25. MST de-
scribes the directedmovement of molecules in solution along a temper-
ature gradient depending on the size, charge and solvation shell of
molecules [36,37].
In this set of experiments, TPPP/p25was ﬂuorescently labeled as de-
scribed in the Materials and methods, then it was titrated with the SYN
or its truncated mutants. As shown in Fig. 4C, the initial ﬂuorescence
values as a function of concentration of SYNor SYN95–140 indicate signif-
icant binding for both SYN and SYN95–140, but a very low one for the
SYN1–120. The ﬂuorescent time traces taken from a representative ex-
periment are shown (Fig. A1A-C). This ﬁnding concerns with that sug-
gested by the ELISA data, namely the binding domain of SYN is
localized within the 121–140 aa region.
3.4. Effect of SYN on the Zn2+-induced structural changes of TPPP/p25
sensed by ANS
It has been shown that the interaction of the two disorder pro-
teins, TPPP/p25 and SYN, does not induce structural changes as de-
tected by circular dichroism spectroscopy [22]. ANS is frequently
used to identify the molten globule structure, but not the globular
or unfolded state of a protein [40,41]. Previously we have reported
that the zinc cation speciﬁcally binds to the zinc binding motif ofTPPP/p25, His61(X)10His72(X)7Cys80(X)2Cys83, promoting the for-
mation of a molten globule structure as detected by ANS ﬂuorescent
assay [18]. We investigated the effect of the binding of various SYN
forms to TPPP/p25 or double truncated TPPP/p25 on the Zn2+-
induced molten globule structure.
Fig. 5A and B show that upon the addition of ANS to TPPP/p25 the
ﬂuorescence intensity increased displaying an emission spectrum
with a maximum at 475 nm. The addition of SYN resulted in a small de-
crease in the ﬂuorescence spectrum of TPPP/p25 with ANS. By adding
Zn2+ to TPPP/p25 in the presence of ANS, the intensity increased, as ex-
pected; however, this effect was completely abolished in the presence
of SYN. This effect reached at 2.5 μM SYN concentration is similar to
that obtainedwith the double truncated TPPP/p25 (Fig. 5C–D), in agree-
mentwith the previous ﬁnding that the core segment of TPPP/p25 is re-
sponsible for SYN binding. This sensitive assay was used to test the
nature of the interaction of TPPP/p25 species with the SYN fragments
(Figs. 5 and A2).
Fig. 5B andD illustrate the results of a series of experiments obtained
by ANS assay. The columns symbol the ﬂuorescence emission of the full
length (Fig. 5B) and the double truncated TPPP/p25 (Fig. 5D) measured
at 475 nm with the different SYN variants at its saturation values
(2.5 μM, except for SYN95–140 fragment and the SYN126–140 peptide,
which are 10 and 100 μM, respectively) in the presence and absence
of zinc. It is worth noting that the addition of either SYN forms to ANS
does not result in alteration in the ﬂuorescence. The Zn2+ is in excess
as compared to the SYNexcluding the possibility that itsmetal ion bind-
ing accounts for the observed alteration.
All these data suggest that a rather loosely packed hydrophobic
core of TPPP/p25 exists in the neighborhood of the zinc ﬁnger motif,
and the addition of Zn2+ promotes a loose molten globule conforma-
tion with marginal stability. However, the effect of Zn2+ is diminished
in the presence of SYN and the fragments (SYN95–140 fragment and
SYN126–140 peptide), which exhibit binding potency to TPPP/p25, pre-
vent the structural rearrangement of the ﬂexible region. In contrast to
this, the SYN1–120 form does not inﬂuence the effect of the bivalent
Zn2+ cation.
Fig. 3. Inhibitory effect of the SYN species on the binding of TPPP/p25 to the SYN afﬁnity
column. TPPP/p25 was loaded to the SYN afﬁnity column in the absence (A) and in the
presence of SYN (B) or SYN1–120 (C) following their premixing as described in the Mate-
rials and methods. A–C: Lane 1, molecular weight marker; lane 2–6, unbound fractions;
lane 7–11, bound fractions; lane 12, proteins loaded to column.
Fig. 4. Effect of the truncation of the SYN on the interaction with TPPP/p25. (A–B) ELISA
experiments. (A) TPPP/p25 was added at different concentrations to the immobilized
SYN (●, solid line), SYN95–140 (◇) or SYN1–120 (△, dotted line), and the bound TPPP/
p25 was detected by polyclonal TPPP/p25 antibody; and the binding afﬁnities (Kd) are
33.9 ± 5.2 nM and 104 ± 32 nM for SYN and SYN1–120, respectively. Error bars represent
SEM (n = 3–9). (B) Competitive ELISA. The plate was coated with SYN, then 0.125 μM
TPPP/p25 was preincubated without (white column) or with 1 μM SYN (black column),
1 μM SYN1–120 (light gray column), 1 μM SYN95–140 (gray column) or 50 μM SYN126–140
peptide (dark gray column), and was added to the immobilized SYN. The binding of
TPPP/p25 to the different SYN species immobilized on the plate was detected by polyclon-
al TPPP/p25 antibody. Binding values relative to the control (no SYN) are shown. Error bars
represent SEM (n = 3–7). (C) Microscale thermophoresis. Binding curves of the various
SYN forms to TPPP/p25. The initial ﬂuorescence is plotted as a function of SYN (●),
SYN95–140 (◇) or SYN1–120 (Δ) concentration. A representative experiment is shown.
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Previouslywe have reported that TPPP/p25 and SYN are co-enriched
and co-localized in neurons and oligodendrocytes in the cases of
Parkinson's disease and MSA, respectively, in spite of the fact that they
are expressed alternatively in normal human brain [2,9]. We also
Fig. 5. Effect of SYN species on themolten globule structure of TPPP/p25 detected by ANS ﬂuorescence. Fluorescence spectra of ANS in the absence (dotted line) and presence of SYN (solid
line), SYN+ Zn2+ (short dashed line), TPPP/p25 (dash-dot-dotted line), TPPP/p25+ Zn2+ (dashed line), TPPP/p25+ SYN (bold line), TPPP/p25+ SYN+ Zn2+ (dash-dotted line). Rep-
resentative emission spectra are shown. (B) Fluorescence values at 475 nmobtained from similar typeof experimentswith the truncated SYN specieswithout (black column) orwith Zn2+
(white column). Error bars represent SEM (n= 3–7). * Signiﬁcant difference with respect to the ANS and TPPP/p25 without Zn2. # Signiﬁcant difference (according to paired Student's t-
test, p b 0.05) between ANS and TPPP/p25 without and with SYN. The concentration of ANS, TPPP/p25, ZnCl2, SYN, SYN1–120, SYN95–140 and SYN126–140 peptide are 50 μM, 2.5 μM, 20 μM,
2.5 μM, 2.5 μM, 10 μM and 100 μM, respectively. (C, D) Similar set of experiments was carried out with the N- and C-terminal free TPPP/p25. ## Signiﬁcant difference between the full
length and the double truncated TPPP/p25 forms with ANS in absence of Zn2+.
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gregate formation, of the wild type human TPPP/p25 and SYN when
these proteins were taken up by CHO10 cells from the medium after
premixing [9].
Nowwehave studied the co-aggregation-proneproperties of the full
length/double truncated TPPP/p25 and the SYN mutants/fragments/
peptide at cellular level in CHO10 cells. The intracellular localization/
co-localization of TPPP/p25 and/or SYNwere visualized by speciﬁc anti-
bodies using red (TPPP/p25) and green (SYN) ﬂuorescently labeled sec-
ondary antibodies as described in details in the Materials and methods
section.
As presented in Fig. 6A and B panels, TPPP/p25 or SYN individually is
transformed into the cells, the uptake of both proteins is virtually exten-
sive, most of the cells are stained with speciﬁc antibodies labeled with
ﬂuorescent dyes; however, no aggregation can be visualized. Co-
aggregates (small yellow spots by merging the red and green ﬂuores-
cent labels) are formed when the full length TPPP/p25 premixed with
SYN or SYN95–140 or FITC-SYN126–140 are taken up from the medium
by the cells (Fig. 6C, E, G) indicating the key role of the very C-
terminal segment of SYN. No aggregation was observed after the treat-
ment of the cells with the mixture of TPPP/p25 and SYN1–120 (data not
shown). When the SYN species were co-transported with the doubletruncated (core) TPPP/p25, a more intensive aggregation was
proceeded showing their massive aggregation-prone potency (Fig. 6D,
F, H). This situation does not represent the formation of inclusions
such as Lewy body; however, it shows the interactive potency of the
segments of the two hallmarks (the core TPPP/p25 and the very C-
terminal of SYN) in the constitution of the contact surface of the patho-
logical hetero-complex as well as validates them as a potential drug
target.4. Conclusions and beyond
NMPs, a subclass of the moonlighting proteins, are frequently major
players in neurological disorders by performing functions at both phys-
iological and pathological conditions due to their heteroassociations
with distinct partner proteins [8]. TPPP/p25 is a prototype of the
NMPs, and it has been deﬁned as a hallmark of synucleinopathies such
as SYN [2]. At pathological conditions these two disordered proteins
are co-enriched and co-localized in brain samples characteristic for
Parkinson's disease andMSA [2,42,43], in spite of the fact, that in normal
brain these two hallmark proteins are expressed distinctly in neurons
and oligodendrocytes, respectively [13,23,24].
Fig. 6. Intracellular aggregates of the heteroassociation of the truncated forms of TPPP/p25
and SYN in CHO10 cells detected by immunoﬂuorescencemicroscopy. Uptake of the trun-
cated forms of SYN and/or the TPPP/p25 by CHO10 cells from themedium following their
premixing as detected by immunoﬂuorescencemicroscopy. Full length (A, C, E, G) or dou-
ble truncated (D, F, H) TPPP/p25 and/or SYN (B, C, D), digested SYN fragments (E, F), FITC-
SYN126–140 (G, H) were taken up by the cells. TPPP/p25 and SYN were immunostained by
rat polyclonal TPPP/p25 and mouse monoclonal (epitope 121DNEAY125) SYN antibodies,
decorated by ﬂuorescently labeled Alexa546 (red, TPPP/p25) and Alexa488 (green, SYN)
secondary antibodies. Note, that the double truncated TPPP/p25 with SYN fragments
forms massive aggregates with co-enrichment of the two proteins. The exposure times
were 1 s, except in the case of D, F, where it had been reduced to 0.1 s, due to the very
high ﬂuorescent intensity of the co-aggregates of TPPP/p25 and SYN (merge). Nuclei
were counterstained with 4,6-diamidino-2-phenylindole (DAPI, blue). Scale bar: 5 μm.
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of research laboratories to develop anti-Parkinson drugs, since it has
multiple functions, in addition, its physiological functions in neurons
have not been identiﬁed in details [20]. The objective of this work was
to present a strategy suitable for the validation of drug targets that is
necessary to develop effective agentswith unique speciﬁcity for therapy
by targeting exclusively the pathological complex. As a ﬁrst step, we
identiﬁed the interface segment of TPPP/p25 [9] and SYN (in this
work) within the TPPP/p25-SYN complex. On one hand, we carried
out in vitro assays usingwild type andmutant human recombinant pro-
teins and fragments, on the other hand, we established a living cell
model which renders it possible to visualize the effectivity and the po-
tency of anti-aggregative drugs.
The fact that both HeLa and CHO10 cells can uptake SYN and TPPP/
p25 has been recently reported [9]. Endocytosis has been suggested
for the mechanism of SYN uptake [44]; and the uptake was found to
be concentration-, time-, and clathrin-dependent [45]. The transcellular
spread of secreted assembled SYN in human H4 neuroglioma cells by
exosomal transmission was demonstrated as well [25]. In addition, the
presence of both SYN and TPPP/p25 was detected in the humancerebrospinal ﬂuid [28,46]. All these data largely contribute to our un-
derstanding how TPPP/p25 and SYN can be enriched in inclusions of
neurons and oligodendrocytes, respectively, in spite of the fact, that
they are expressed alternatively in the two cell types In addition, and
they may open the door to a new innovative strategy in anti-
Parkinson research. Thus, themessage of the present paper is of general
scope, namely that proteins with neomorphic moonlighting functions
should not be speciﬁc drug targets, rather the interfaces of their patho-
logical complexes.
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